What the Research Says
Berberine has strong clinical evidence for metabolic benefits. Yin et al. (2008) published a landmark trial showing berberine lowered fasting blood glucose and HbA1c comparably to metformin in type 2 diabetes patients. A 2019 systematic review by Liang et al. confirmed these findings across multiple trials. Zhang et al. (2008) demonstrated combined benefits for both blood sugar and dyslipidemia. The AMPK activation mechanism is well-characterized in pharmacological studies, providing a clear biological basis for its metabolic effects.